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SUMMARY
The prevalence and consequences of nasal obstruction in untreated
obstructive sleep apnea patients are not known. The study objectives
were to investigate the frequency of subjective and objective nasal
obstruction in untreated sleep apnea patients and the associations with
sleep and quality of life. Patients in the Icelandic Sleep Apnea Cohort
were subjected to a type 3 sleep study, answered questionnaires and
had their nasal dimensions measured by acoustic rhinometry. In total,
810 patients participated (including 153 females), aged
54.5  10.6 years [mean  standard deviation (SD)] with an apnea/
hypopnea index 44.7  20.7 h1. Nocturnal nasal obstruction (greater
than or equal to three times per week) was reported by 35% of the
patients. These patients had smaller nasal dimensions measured by the
minimum cross-sectional area within the smaller nasal valve
(0.42  0.17 versus 0.45  0.16 cm2, P = 0.013), reported more day-
time sleepiness (Epworth Sleepiness Scale score 12.5  4.9 versus
10.8  5.0; P < 0.001) and slightly lower mental quality of life than
patients without nocturnal nasal obstruction. Nocturnal nasal obstruction
is reported in one-third of the sleep apnea patients and they are more
likely to suffer from daytime sleepiness and slightly reduced quality of life
than other sleep apnea patients.
INTRODUCTION
Healthy people normally breathe through the nose during
sleep, with only 0–4% of the sleeping time reported as oral
breathing (Fitzpatrick et al., 2003). Nasal obstruction is a
problem reported by approximately 15% of the general
population (Eriksson et al., 2011), with decreased quality of
life as consequence (Hellgren, 2007). Several structural
problems may cause reduced nasal patency, including septal
deviation, enlarged turbinates and nasal valve collapse.
Moreover, inﬂammatory diseases of the nasal mucosa, such
as allergic and non-allergic rhinitis, as well as chronic
rhinosinutis with and without nasal polyposis, can cause
nasal obstruction (Georgalas, 2011). We have reported
recently that patients with nasal obstruction due to chronic
rhinosinusitis with nasal polyps had impaired sleep quality
that improved with surgery, and that the obstructive sleep
apnea (OSA) risk was also decreased (V€arendh et al., 2017).
Obstructive sleep apnea is a common disease, affecting
25–50% of middle-aged people in the general population
(Heinzer et al., 2015). Using questionnaires, Hoffstein et al.
(1992) asked patients for side effects during continuous
positive airway pressure (CPAP) treatment and reported that
nasal obstruction was a common issue. However, the degree
of nasal symptoms before CPAP treatment was not reported,
and the patients had been on CPAP for varying lengths of
time. Krakow et al. (2016) studied non-allergic nasal obstruc-
tion retrospectively in patients referred to a sleep
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investigation, but they did not specify differences in nasal
obstruction between patients with and without OSA. Further-
more, they found more daytime sleepiness in patients with
non-allergic nasal obstruction. No randomized controlled
study has shown effect of nasal surgery on the apnea–
hypopnea index (AHI) (Koutsourelakis et al., 2008), but one
meta-analysis showed a minor effect (Wu et al., 2017). Two
small meta-analyses by Ishii et al. (2015) and Li et al. (2011)
concluded that nasal surgery in OSA patients with nasal
obstruction leads to a decline in daytime sleepiness.
Several papers state that many OSA patients have nasal
obstruction, but no well-deﬁned, large studies have
addressed the prevalence of subjective and objective nasal
obstruction in these patients before initiating treatment. The
pathophysiological role of the nose and the consequences of
nasal obstruction for health-related quality of life in OSA are
therefore not understood fully. Accordingly, the objectives of
this study were to investigate the frequency of subjective and
objective nasal obstruction in OSA patients while untreated,
and to assess if nasal obstruction was associated with sleep-
related symptoms and quality of life.
Our hypothesis was that subjective nocturnal nasal
obstruction is common in OSA patients and is associated
with objective narrowing of one nasal passage. Moreover, we
hypothesized that nasal obstruction would inﬂuence insomnia
and some other aspects of sleep quality or quality of life.
METHODS
Study design and study subjects
This is a cross-sectional study. The Icelandic Sleep Apnea
Cohort (ISAC) is a project with the overall aim of studying the
genetics of OSA. The project is performed in collaboration
between the University of Iceland Reykjavik, Iceland and the
University of Pennsylvania, USA. The major project is divided
into many smaller studies, investigating different aspects of
the OSA disease. Patients diagnosed with OSA who were
referred to the Department of Respiratory Medicine and
Sleep, Landspitali—The National University Hospital (LSH) of
Iceland—for treatment with positive airway pressure (PAP)
from September 2005 to December 2009 were invited to
participate in the ISAC study. More than 90% of eligible and
approached subjects (n = 822) agreed to participate and
started PAP treatment following baseline assessment. Nine
patients were excluded due to missing acoustic rhinometry
(AR) data and one withdrew from the study (Fig. 1).
Furthermore, two patients were excluded, as they did not
answer the question concerning nocturnal nasal obstruction.
No other exclusion or inclusion criteria were used (Arnardottir
et al., 2013). The National Bioethics Committee of Iceland,
the Data Protection Authority of Iceland and the Institutional
Review Board of the University of Pennsylvania approved
the ISAC study. All patients signed a written informed
consent.
Measurements and questionnaires
While untreated, the patients answered standardized ques-
tionnaires about their health and sleep. Nasal obstruction was
evaluated with the question: ‘Is your nose congested at night?’.
The response categories were a frequency scale from 1 to 5:
1 = never or very seldom, 2 = less than once a week,
3 = once to twice a week, 4 = 3–5 times a week, and
5 = every night or almost every night of the week. A score of
4 or 5 was deﬁned as nocturnal nasal obstruction. Patients
completed the questionnaires the same day or, for some within
the days before, were examined with Acoustic Rhinometry.
The Basic Nordic Sleep Questionnaire was used to evaluate
sleep symptoms including insomnia symptoms (Partinen and
Gislason, 1995). The following questions were asked: ‘I have
difﬁculties falling asleep at night’ (initial insomnia), ‘I wake up
often during the night’ (middle insomnia) and ‘I wake up early
and ﬁnd it difﬁcult to fall back asleep’ (late insomnia).
Symptoms of insomnia were considered present if reported
three times per week or more often. All questions were based
on the past month’s experience. Nocturnal sweating was also
considered present if reported three times per week or more
often. Nocturnal gastroesophageal reﬂux was considered
present if reported more than once per week (Emilsson et al.,
2012; Gislason et al., 2002).
Daytime sleepiness was evaluated with the Epworth
Sleepiness Scale (ESS), and an ESS score of ≥10 was
considered excessive daytime sleepiness (Johns, 1991).
Health-related quality of life was examined with the Short
Form Health Survey (SF-12) questionnaire (Ware et al.,
1996). Scores are divided into either physical or mental
Patients included 
All subjects
n = 822
n = 821
n = 819
Subjects in analysis
n = 810
Withdrawal
n = 1
No AR
n = 9
Did not answer question on
nocturnal nasal obstruction
n = 2
Figure 1. Outline of the patient sample.
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health scores. Physical health is exempliﬁed as moving a
table or climbing several ﬂights of stairs and if physical
activities were limited due to compromised physical health.
Concerning mental health, patients were asked if emotional
issues such as feeling depressed or anxious have limited
their daily activities. The scores range from 0 to 100 (score of
100 indicates the best health-related quality of life).
Patients were also asked if they were on nasal cortisone
medication (yes/no).
Acoustic rhinometry
The AR technique works through an acoustic pulse sent into
the nostrils. A single-impulse rhinometer (RhinoScanTM
SRE2000; Rhinometrics, Assens, Denmark) was used. The
method provides an anatomical description of the measure-
ments of the nasal cavity. It compares the amplitude
(representing the area) of sound waves that are reﬂected
by the structures in the nasal cavity of an incident sound
wave as a function of time (representative for the distance to
the nasal cavity) (Clement and Gordts, 2005). Patients were
examined sitting in an upright position.
The variables examined before nasal spray were: total
minimal cross-sectional area in both nasal valves added
together (TMCA, cm2), minimal cross-sectional area within
the smaller nasal valve (either left or right) (MCA-min, cm2),
total volume of left and right nasal cavity added together
(TVOL, cm3) and the difference between MCA before and
after nasal decongestive spray (MCA-diff, cm2). The decon-
gestive spray, oxymethazoline (0.5 mg/ml) was given with
two puffs in each nostril after the ﬁrst AR. All AR measure-
ments were re-evaluated on 2–6 of November 2015 by M.V.
Three measurements were not of sufﬁcient quality and were
not used in calculations.
Sleep study
A type 3 sleep study was conducted with an Embletta
portable monitor, an Embla 12 channel system (EmblaTM;
Flaga Inc., Reykjavik, Iceland) or a T3 device (Nox Medical,
Reykjavik, Iceland). All systems recorded the same channels.
The sleep study included nasal airﬂow, oxygen desaturation,
pulse, chest and abdominal movements by respiratory
inductive plethysmography as well as body position and
activity by accelerometer.
All sleep studies were re-read by a centralized scoring
laboratory at the University of Pennsylvania using the
Somnologica Studio (EmblaTM) software and were used for
the analysis. More than 4 h of a scorable oxygen saturation
(SaO2) signal was needed for a sleep study to be scored. The
AHI was deﬁned as the mean number of apnea and
hypopnea per hour of recording (upright time excluded). A
hypopnea was classiﬁed as ≥30% decrease in the ﬂow with
≥4% oxygen desaturation or ≥50% decrease in ﬂow for
≥10 s, with a sudden increase in ﬂow at the end of the event.
The oxygen desaturation index (ODI) was deﬁned as the
number of transient drops in oxygen saturation ≥4% per hour
of recording. OSA severity was deﬁned as: severe OSA
(AHI ≥ 30), moderate OSA (AHI 15–29.9) and mild OSA (AHI
5–14.9). See previous publications for further details (Arnar-
dottir et al., 2012).
Nasal surgery
Information on prior nasal surgery was derived from patient
ﬁles, including septoplasty, turbinectomy and endoscopic
surgery, sometimes with polypectomy.
Statistical analysis
Nominal data were presented as frequencies and percent-
ages without decimals. In comparisons between nominal
data in independent groups, the chi-squared test was used.
Fisher’s exact test was used when the expected values were
insufﬁcient for a chi-squared test. Ordinal and quantitative
data were presented by mean and standard deviation ( SD).
Independent group differences were calculated with the
Mann–Whitney U-test for two groups and Kruskal–Wallis test
for more than a two-group comparison. Post-hoc tests were
calculated with the Mann–Whitney U-test between two
groups when the Kruskal–Wallis test showed a signiﬁcance
of <0.05 for more than two-group comparisons. Multiple
Logistic regression analyses were calculated with the Enter
method; SPSS version 22.0 was used in all analyses. A two-
sided P-value of <0.05 was considered signiﬁcant in all
calculations. All P-values, signiﬁcant or not, are presented in
the comparisons.
RESULTS
Study sample
The characteristics of the patients are shown in Table 1 (153
females and 657 males). The mean  SD BMI was
33.5  5.7 kg m2. A large proportion of the patients (57%)
was diagnosed with hypertension; 21% were current smokers
and 27% were former smokers. Hypertension was more
frequent in females (P < 0.05). Daytime sleepiness was
common, and the overall mean score for ESS was
11.7  5.0 (mean  SD). Also, the SF-12 survey demon-
strated a low mental and physical health-related quality of life.
A larger proportion of the women reported nocturnal sweat-
ing, nocturnal gastric reﬂux and insomnia (both initial, middle
and late) (P < 0.05).
A majority of the patients (73%) had severe OSA; 23% had
moderate OSA and 3% had mild OSA.
Prevalence of subjective and objective nasal obstruction
in OSA
Overall, 65% reported nasal obstruction during the night once
per week or more often and 35% greater than or equal to
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three times per week. No signiﬁcant differences were seen in
OSA severity, as measured by the AHI, between the three
groups (P = 0.57) (Table 2).
Nasal cavity dimensions assessed by AR showed mean
values of TMCA 1.06  0.31, MCA-min 0.43  0.16 and
TVOL 4.10  0.81. TMCA and TVOL were signiﬁcantly
smaller in female patients than in males (P < 0.05) but no
sex differences were found in subjective nocturnal nasal
obstruction; see Table 1.
Sleep-related symptom and nocturnal nasal obstruction
We divided the patients into three groups, depending on their
subjective nocturnal nasal obstruction symptoms (Table 2).
Women and men were distributed equally between the three
groups (P = 0.45). There was a difference between the
groups in MCA-min, assessed by AR, with the smallest mean
value of 0.42  0.17 cm2 in the nocturnal nasal obstruction
group compared to 0.45  0.16 cm2 in the group without any
nocturnal nasal obstruction (post-hoc analysis between
‘never nasal obstruction’ and ‘greater than or equal to three
times per week’, P = 0.013) (Table 2).
Late insomnia was reported by a larger proportion of the
patients with nocturnal nasal obstruction more than three
times per week compared to the group without (post-hoc:
P = 0.013) (Fig. 2, P-value = 0.005 is calculated between all
three groups); 65% of patients with nocturnal nasal obstruc-
tion greater than or equal to three times per week week have
middle insomnia. Patients with nocturnal nasal obstruction
also had more daytime sleepiness compared to patients
Table 1 Women had smaller nasal dimensions, more insomnia and a lower quality of life
Baseline characteristics, nasal dimensions and sleep quality (n = 810)
All
n = 810
Female
n (%)
153 (19)
Male
n (%)
657 (81)
P-value for
sex comparison
Age (years) 54.5  10.6 58.6  9.0 53.6  10.8 <0.001
Current smoker 21% 19% 22% 0.58
Body mass index (kg m2) 33.5  5.7 34.1  6.3 33.3  5.5 0.19
Weight (kg) 104.3  19.2 93.0  17.2 106.9  18.7 <0.001
Hypertension 57% 67% 55% 0.03
Diabetes 11% 12% 11% 0.70
Coronary heart disease including coronary
heart occlusion, heart failure or/and stroke
18% 10% 20% 0.006
Apnea–hypopnea index 44.8  20.7 42.2  20.0 45.4  20.8 0.058
Oxygen desaturation index (4%) 35.5  20.3 32.6  20.5 36.2  20.2 0.008
Nocturnal nasal obstruction ≥3 9 week 35% 37% 35% 0.68
TMCA (cm2) 1.06  0.31 0.94  0.28 1.08  0.31 <0.001
MCA-min (cm2) 0.43  0.16 0.40  0.15 0.44  0.17 0.02
TVOL (cm3) 4.10  0.81 3.48  0.65 4.25  0.77 <0.001
Diff TMCA (cm2) 0.19  0.21 0.16  0.20 0.20  0.22 0.02
Diff MCA-min (cm2) 0.10  0.12 0.08  0.11 0.11  0.12 0.03
Diff TVOL (cm3) 0.21  0.34 0.22  0.31 0.21  0.35 0.30
Nocturnal gastroesophageal reﬂux ≥ 1 9 week 14% 18% 13% 0.006
Initial insomnia, ≥3 9 per week 16% 27% 13% <0.001
Middle insomnia, ≥3 9 per week 58% 62% 57% <0.001
Late insomnia, ≥3 9 per week 28% 33% 27% <0.001
Nocturnal sweating ≥3 9 per week 31% 33% 31% <0.001
Daytime sleepiness (ESS) 11.7  5.0 11.2  5.2 11.8  5.0 0.23
Mental quality of life (SF-12) 48.3  10.9 46.8  11.1 48.6  10.8 0.048
Physical quality of life (SF-12) 40.2  10.9 35.5  10.9 41.3  10.6 <0.001
ESS, Epworth sleepiness scale; Diff MCA-min, difference between MCA-min before and after nasal decongestant spray; Diff TMCA,
difference between TMCA before and after nasal decongestant spray; Diff TVOL, difference between before and after nasal decongestant
spray; MCA-min, minimal cross-sectional area within the smallest nostril of either left or right before decongestant spray; TMCA, total minimal
cross-section area in the nose, left and right nostril combined before nasal decongestant spray; TVOL, total volume of left and right nasal
volume combined before nasal decongestant spray
SF-12: The 12-Item Short Form Health Survey (SF-12), a smaller version of the SF-36 version 2 Health Survey.
MCA: minimal cross-sectional area within one nasal valve, before nasal decongestant spray; TVOL: total volume of left and right nasal
volume combined before nasal decongestant spray.
Signiﬁcance shown in bold type.
Numbers given as mean  standard deviation if not speciﬁed, and P-values when comparing mean values calculated with Mann–Whitney
U-test.
The chi-squared test was used for comparisons between nominal data in independent groups (here shown as %).
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without nocturnal nasal obstruction (ESS: 12.5  4.9 versus
10.8  5.0, post-hoc comparison, P < 0.001) (Fig. 3). Mental
quality of life was reported lower in the group with nocturnal
nasal obstruction compared to those without obstruction
(46.4  11.4 versus 49.8  10.5, P < 0.001) (Fig. 3).
A multiple regression analysis was performed to predict
subjective nocturnal nasal obstruction. The differences found
in subjective nocturnal nasal obstruction remained signiﬁcant
after adjusting for sex, BMI, nocturnal gastroesophageal
reﬂux and smoking.
Nasal surgery
A total of 86 patients had nasal surgery prior to PAP
treatment and prior to being included in the study. Some
patients underwent more than one kind of surgery and 18
patients underwent nasal surgery on two occasions. The
different surgeries were: septal deviation surgery (61),
turbinoplasty (37) and endoscopic sinus surgery and
Table 2 Patients with frequent nocturnal nasal obstruction were slightly more likely to have one smaller nasal valve; no other signiﬁcant
differences were found between the groups
Nocturnal nasal obstruction (n = 810)
Never
n = 285
1–2 9 per week
n = 240
≥3 9 per week
n = 285 P-value
Age (years) 55.4  10.4 53.7  10.3 54.1  11.0 0.16
Current smoker 21% 27% 20% 0.85
Body mass index (kg m2) 33.7  5.8 33.1  5.6 33.6  5.6 0.30
Apnea–hypopnea index 43.5  10.0 45.8  20.5 45.2  21.5 0.57
Oxygen desaturation index 34.3  19.8 36.1  20.0 36.3  20.9 0.54
TMCA (cm2) 1.11  0.30 1.07  0.30 1.03  0.32 0.19
MCA-min (cm2) 0.45  0.16 0.44  0.17 0.42  0.17 0.04*
TVOL (cm3) 4.10  0.83 4.13  0.78 4.08  0.81 0.78
Diff TMCA (cm2) 0.17  0.21 0.21  0.19 0.20  0.23 0.11
Diff MCA-min: difference between MCA-min before and after nasal decongestant spray; Diff TMCA: difference between TMCA before and
after nasal decongestant spray
Diff TVOL: difference between before and after nasal decongestant spray; CA-min: minimal cross-sectional area within the smallest nostril of
either left or right before decongestant spray
TMCA: total minimal cross-section area in the nose, left and right nostril combined before nasal de-obstruction spray; TVOL: total volume of
left and right nasal volume combined before nasal decongestant spray. Signiﬁcance shown in bold type.
Numbers given as mean  standard deviation if not speciﬁed.
Independent group differences were calculated with Kruskal–Wallis test for >2-group comparison of mean values.
The chi-squared test was used for comparisons between nominal data in independent groups (here shown as %).
*P-value for post-hoc test: 0.013 comparing the groups ‘Never’ and ‘≥ 3 9 per week’.
×
×
Figure 2. Patients with nocturnal nasal obstruction are more likely to
have late insomnia and 65% of patients with nocturnal nasal
obstruction greater than or equal to three times per week have
middle insomnia. **Signiﬁcance between the groups of patients
without and with nocturnal nasal obstruction greater than or equal to
three times per week. N-GER, nocturnal gastroesophageal reﬂux.
×
×
Figure 3. Patients with more nocturnal nasal obstruction have more
daytime sleepiness and lower scores on quality of life, mental
section. The ﬁgure describes nocturnal nasal obstruction and
daytime sleepiness (ESS, Epworth Sleepiness Scale) and quality
of life measured by SF-12. **Signiﬁcant difference between the
groups of patients without and with nocturnal nasal obstruction
greater than or equal to three times per week.
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polypectomy (11). As a group, these patients reported
signiﬁcantly more frequent nasal obstruction compared to
the others, despite surgery (47% versus 34%, respectively,
P = 0.02), but no differences were found in OSA severity or
measured nasal dimensions (Table 3).
Medication
Concerning medication with a possible impact on nasal
obstruction, the following results were found: 37 patients
used nasal steroids, 14 patients systemic steroids and six
patients oral antihistamines. A total of 55 patients had one or
more of these medications. However, there were no differ-
ences between the users of these drugs and non-users in
terms of AHI (P = 0.8), TMCA (P = 0.34), MCA-min
(P = 0.77) or TVOL (P = 0.66).
DISCUSSION
The present study demonstrates that the prevalence of
reported nocturnal nasal obstruction was 35% in untreated
OSA patients. Patients with nocturnal nasal obstruction
were more likely to have one small nasal valve area (MCA-
min). Moreover, OSA patients with nasal obstruction
reported symptoms of late insomnia and daytime sleepi-
ness slightly more often, and generally had a lower mental
quality of life compared to OSA patients without nasal
obstruction.
Prevalence of nocturnal nasal obstruction
The present study revealed a nocturnal nasal obstruction
prevalence of almost 65% once per week or more often and
35% greater than or equal to three times in treatment-naive
OSA patients. To our knowledge, the prevalence of nasal
obstruction in OSA has not been described previously. A
previous retrospective study reported a prevalence of non-
allergic nasal obstruction of 45% in unselected sleepy
patients (Krakow et al., 2016). The Wisconsin Sleep Cohort
reported nasal obstruction to be a risk factor for apneas,
hypopneas and habitual snoring (Young et al., 1997). How-
ever, they did not report a prevalence of nasal obstruction in
patients with OSA.
Acoustic rhinometry
The minimal cross-section area within the smallest nasal
valve of either left or right side, MCA-min, was the only
parameter that was found to differ between OSA patients with
and without nasal obstruction. In contrast to our results,
Vidigal et al. (2013) used AR to study the nasal geometry in a
small sample of OSA patients and a control group. They
found more nasal symptoms in OSA patients compared to
controls, but no difference in AR values. However, they did
not investigate the smallest nasal valve compared to
subjective obstruction.
There are at least two elements of nasal obstruction.
The ﬁrst is the structural part consisting of skeletal bone
and cartilage and the second is the swollen mucosa
causing congestion. The latter varies with the nasal cycle,
the normal ‘corporo-nasal’ reﬂex, and possibly a separate
airﬂow cycle within each nasal valve (Kahana-Zweig
et al., 2016). These normal events could explain the
inﬂuence of MCA-min on subjective nasal obstruction in
the current study. If one side of the nose is obstructed
structurally, subjective nasal obstruction will increase if
subjects lie on their other side; the more open (lower)
half of the nose that becomes congested, the more
resistant (upper) half of the nose will not be patent
(Pevernagie et al., 2005).
OSA severity between the groups
No differences were observed in OSA severity between
the patients with and without nocturnal nasal obstruction.
No other large study has, to our knowledge, investigated
the relation between AHI and nocturnal nasal obstruction.
There are conﬂicting results concerning OSA severity and
impact of nasal surgery. Two previously mentioned meta-
analyses by Ishii et al. (2015) and Li et al. (2011)
included small, and only randomized and controlled,
studies. These studies showed no improvement on OSA
severity with nasal surgery. One small meta-analysis of
Wu et al. (2017) showed an improvement of OSA severity
with surgery.
Table 3 Former nasal surgery had no impact on AHI or nasal
dimensions; a larger proportion of patients with previous nasal
surgery were reporting nocturnal nasal obstruction
Former nasal surgery
Nasal surgery
n (%)
86 (11)
No nasal surgery
n (%)
724 (89) P-value
Apnea–hypopnea
index
40.7  16.2 45.3  21.1 0.12
TMCA (cm2) 1.05  0.30 1.05  0.31 0.99
MCA-min (cm2) 0.43  0.16 0.43  0.17 0.95
TVOL (cm3) 4.06  0.75 4.11  0.81 0.84
Nocturnal nose
obstruction
47% 34% 0.02
MCA-min: minimal cross-sectional area within the smallest nostril
of either left or right before decongestant spray; TMCA: total
minimal cross-section area in the nose, left and right nostril
combined before nasal decongestant spray; TVOL: total volume of
left and right nasal volume combined before nasal decongestant
spray.
Signiﬁcance shown in bold type.
Numbers given as mean  standard deviation if not speciﬁed, and
P-values when comparing mean values were calculated with the
Mann–Whitney U-test.
The chi-squared test was used comparisons between nominal
data in independent groups (here shown as %).
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Insomnia
Late insomnia was reported more often by patients with
nocturnal obstruction compared to OSA patients without nasal
obstruction (P = 0.01) despite similar OSA severity. This
ﬁnding is in line with a previous study that reported more
insomnia problems in patients with undifferentiated sleep
problems and nasal obstruction than in patients without these
problems.However, it wasa retrospective questionnaire study,
and the patients were not diagnosed with OSA (Krakow et al.,
2016). It is possible that nocturnal nasal obstruction has an
inﬂuence on late insomnia in OSA patients.
Daytime sleepiness
Daytime sleepiness was found to be more slightly more
pronounced in OSA patients with nocturnal nasal obstruction
compared to patients without obstruction (P < 0.001). With a
mean value of 12.5  4.9, the sleepiness will most probably
have an impact upon everyday life. Our results are therefore
in agreement with previous studies showing that nasal
obstruction has an impact upon daytime sleepiness (Ishii
et al., 2015; Li et al., 2011; V€arendh et al., 2017).
Quality of life
Mental quality of life in patients with nasal obstruction was
found to be slightly lower than in other OSA patients
(P < 0.001) and lower compared to normal reference values
for healthy adults (Hilberg, 2002). This matter has not, to our
knowledge, been studied previously. A possible explanation
for the decreased quality of life is that patients are inﬂuenced
by their nasal obstruction, which is associated with more
insomnia complaints and daytime sleepiness. Nocturnal
nasal obstruction might increase the problems of insomnia
and daytime sleepiness, which inﬂuences quality of life.
Medication
Using oral antihistamines, nasal or systemic corticosteroids
did not have an impact upon nasal dimensions.
Strengths and limitations of the study
A major strength of this study is the large, well-deﬁned clinical
cohort of OSA patients in ISAC and that the nose is examined
both subjectively and objectively.
Acoustic rhinometry is a valid technique provided that the
limitations are understood (Arnardottir et al., 2016; Clement
and Gordts, 2005). The method describes anatomical struc-
tures, but does not give extensive information about nasal
function. AR is conducted in an upright position during the
daytime and therefore it is difﬁcult to draw conclusions about
nasal dimensions during sleep. However, an anatomical
description of OSA patients prior to treatment is lacking in the
literature, and is of interest and importance.
Sleep was recorded with a type 3 sleep study without
electroenceophalography (EEG), and therefore it was not
possible to study arousals. However, a type 3 sleep study is
clinically acceptable for the diagnosis OSA (Berry et al.,
2015; Mols et al., 2009). A limitation to the objective
evaluation of insomnia in this study is that polysomnography
was not used.
The nasal questions used were not validated and addi-
tional validated questionnaires, such as the Sino-Nasal
Outcome Test (SNOT-22), would probably have provided a
better evaluation of the patients’ symptoms. Questionnaires
have limitations, but subjective symptoms of patients are
extremely valuable and important. It is difﬁcult to obtain
objective measurements in some issues in real-life circum-
stances, and the patient’s complaint indicates what is
affecting her/his quality of life.
A control group of healthy individuals would have been of
major interest, but to gather such a large group of non-sleep-
apnea patients of comparable age, sex and weight remains a
future task.
Clinical implications
The ﬁndings in this study show that it is of great importance to
increase the awareness of clinicians of the high incidence of
nasal obstruction is OSA patients and how much it inﬂuences
their daily life.
CONCLUSION
Nocturnal nasal obstruction was found in more than one-third
of the OSA patients. Subjects with nocturnal nasal obstruc-
tion had, on average, one nasal valve with a smaller
minimum cross-section area. Furthermore, measures of late
insomnia, daytime sleepiness and mental quality of life were
slightly worse compared to patients without nasal obstruction.
ACKNOWLEDGEMENTS
We would like to thank Sigrun Gudmundsdottir and Lovisa
Gudmundsdottir for data collection and Eyjolfur Sigurdsson
for statistical preparations. A special thank you to Professor
Robin L. Anderson, Peter MacCallum Cancer Centre and the
University of Melbourne for English proofreading and a
valuable review of the manuscript. The authors are also
thankful to Allan I. Pack, Greg Maislin, Bethany Staley,
Brendan Keenan and the other staff at the Centre for Sleep
and Circadian Neurobiology at the University of Pennsylvania
who helped to analyse the sleep studies and other data of the
cohort. NIH supported this project, grant number:
R01HL072067.
AUTHOR CONTRIBUTIONS
MV took part in designing the calculations, in evaluating the
results, performed statistical calculations and drafted the
ª 2017 The Authors. Journal of Sleep Research published by John Wiley & Sons Ltd on behalf of European Sleep Research Society.
Frequency of nasal obstruction and sleep quality 7
paper. MA contributed to designing the calculations, took part
in evaluating the results and reviewed the paper. EB
contributed to designing the calculations, took part in eval-
uating the results and reviewed the manuscript. HH-S
contributed to designing the calculations, took part in eval-
uating the results and reviewed the manuscript. AJ con-
tributed to statistical analysis design and performed statistical
calculations and analysis. ESA designed the study, con-
tributed to designing the calculations, took part in evaluating
the results and reviewed the manuscript. TG designed the
study, contributed to designing the calculations, took part in
evaluating the results and reviewed the manuscript. SJ
designed the study, participated in data collection, con-
tributed to designing the calculations and took part in
evaluating the results. All authors participated in all revisions
of the paper with co-authors.
CONFLICT OF INTERESTS
MV, MA, EB, AJ, TG and SJ: no conﬂicts of interest. HH-S
received payments for lectures from the NOX, TAKEDA and
RESmed companies outside the submitted work. ESA is part-
time consultant for Nox Medical, Reykjavik, Iceland unrelated
to this paper, outside the submitted work.
REFERENCES
Arnardottir, E. S., Maislin, G., Schwab, R. J. et al. The interaction of
obstructive sleep apnea and obesity on the inﬂammatory markers
C-reactive protein and interleukin-6: the Icelandic Sleep Apnea
Cohort. Sleep, 2012, 35: 921–932.
Arnardottir, E. S., Janson, C., Bjørnsdottir, E. et al. Nocturnal
sweating – a common symptom of obstructive sleep apnoea: the
Icelandic sleep apnoea cohort. BMJ Open, 2013, 3: e002795.
Arnardottir, E. S., Verbraecken, J., Goncalves, M. et al. Variability in
recording and scoring of respiratory events during sleep in Europe:
a need for uniform standards. J. Sleep Res., 2016, 25: 144–157.
Berry, R. B., Gamaldo, C. E., Harding, S. M. et al. AASM Scoring
Manual Version 2.2 updates: new chapters for scoring infant sleep
staging and home sleep apnea testing. J. Clin. Sleep Med., 2015,
11: 1253–1254.
Clement, P. A. and Gordts, F. Consensus report on acoustic
rhinometry and rhinomanometry. Rhinology, 2005, 43: 169–179.
Emilsson, O. I., Janson, C., Benediktsdottir, B., Julıusson, S. and
Gıslason, T. Nocturnal gastroesophageal reﬂux, lung function and
symptoms of obstructive sleep apnea: results from an epidemio-
logical survey. Respir. Med., 2012, 106: 459–466.
Eriksson, J., Ekerljung, L., Pullerits, T. et al. Prevalence of chronic
nasal symptoms in West Sweden: risk factors and relation to self-
reported allergic rhinitis and lower respiratory symptoms. Int. Arch.
Allergy Immunol., 2011, 154: 155–163.
Fitzpatrick, M., Driver, H., Chatha, N., Voduc, N. and Girard, A.
Partitioning of inhaled ventilation between the nasal and oral routes
during sleep in normal subjects. J. Appl. Physiol. (1985), 2003, 94:
883–890.
Georgalas, C. The role of the nose in snoring and obstructive sleep
apnoea: an update. Eur. Arch. Otorhinolaryngol., 2011, 268: 1365–
1373.
Gislason, T., Janson, C., Vermeire, P. et al. Respiratory symptoms
and nocturnal gastroesophageal reﬂux: a population-based study
of young adults in three European countries. Chest, 2002, 121:
158–163.
Heinzer, R., Vat, S., Marques-Vidal, P. et al. Prevalence of sleep-
disordered breathing in the general population: the HypnoLaus
study. Lancet Respir. Med., 2015, 3: 310–318.
Hellgren, J. Quality of life in nonallergic rhinitis. Clin. Allergy
Immunol., 2007, 19: 383–387.
Hilberg, O. Objective measurement of nasal airway dimensions using
acoustic rhinometry: methodological and clinical aspects. Allergy,
2002, 57(Suppl. 70): 5–39.
Hoffstein, V., Viner, S., Mateika, S. and Conway, J. Treatment of
obstructive sleep apnea with nasal continuous positive airway
pressure. Patient compliance, perception of beneﬁts, and side
effects. Am. Rev. Respir. Dis., 1992, 145: 841–845.
Ishii, L., Roxbury, C., Godoy, A., Ishman, S. and Ishii, M. Does nasal
surgery improve OSA in patients with nasal obstruction and OSA?
A meta-analysis. Otolaryngol. Head Neck Surg., 2015, 153: 326–
333.
Johns, M. W. A new method for measuring daytime sleepiness: the
Epworth sleepiness scale. Sleep, 1991, 14: 540–545.
Kahana-Zweig, R., Geva-Sagiv, M., Weissbrod, A. and Secundo, L.,
Soroker, N. and Sobel, N. Measuring and characterizing the
human nasal cycle. PLoS ONE, 2016, 11: e0162918.
Koutsourelakis, I., Georgoulopoulos, G., Perraki, E., Vagiakis, E.,
Roussos, C. and Zakynthinos, S. G. Randomised trial of nasal
surgery for ﬁxed nasal obstruction in obstructive sleep apnoea.
Eur. Respir. J., 2008, 31: 110–117.
Krakow, B., Foley-Shea, M., Ulibarri, V. A., McIver, N. D. and
Honsinger, R. Prevalence of potential nonallergic rhinitis at a
community-based sleep medical center. Sleep Breath, 2016, 20:
987–993.
Li, H. Y., Wang, P. C., Chen, Y. P., Lee, L. A., Fang, T. J. and Lin, H.
C. Critical appraisal and meta-analysis of nasal surgery for
obstructive sleep apnea. Am. J. Rhinol. Allergy., 2011, 25: 45–49.
Mols, M., Pelle, A. B. and Kupper, N. Normative data of the SF-12
health survey with validation using postmyocardial infarction
patients in the Dutch population. Qual. Life Res., 2009, 18: 403–
414.
Partinen, M. and Gislason, T. Basic Nordic Sleep Questionnaire
(BNSQ): a quantitated measure of subjective sleep complaints. J.
Sleep Res., 1995, 4: 150–155.
Pevernagie, D. A., De Meyer, M. M. and Claeys, S. Sleep, breathing
and the nose. Sleep Med. Rev., 2005, 9: 437–451.
V€arendh, M., Johannisson, A., Hrubros-Strøm, H. and Andersson, M.
Sleep quality improves with endoscopic sinus surgery in patients
with chronic rhinosinusitis and nasal polyposis. Rhinology, 2017,
55: 45–52.
Vidigal, T. A., Haddad, F. L. M., Gregorio, L. C., Poyares, D., Tuﬁk, S.
and Bittencourt, L. R. A. Subjective, anatomical, and functional
nasal evaluation of patients with obstructive sleep apnea syn-
drome. Sleep Breath., 2013, 17: 427–433.
Ware, J., Kosinski, M. and Keller, S. D. A 12-Item Short-Form Health
Survey: construction of scales and preliminary tests of reliability
and validity. Med. Care, 1996, 34: 220–233.
Wu, J., Zhao, G., Li, Y. et al. Apnea–hypopnea index decreased
signiﬁcantly after nasal surgery for obstructive sleep apnea: a
meta-analysis. Medicine (Baltimore), 2017, 96: e6008.
Young, T., Finn, L. and Kim, H. Nasal obstruction as a risk
factor for sleep-disordered breathing. The University of Wiscon-
sin Sleep and Respiratory Research Group. J. Allergy Clin.
Immunol., 1997, 99: S757–S762.
ª 2017 The Authors. Journal of Sleep Research published by John Wiley & Sons Ltd on behalf of European Sleep Research Society.
8 M. V€arendh et al.
